Monopar Therapeutics (MNPR) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 97.5% versus a loss of 21.8%. Over five years, MNPR leads with a +221.6% price change compared with +70.1% for PBYI. Puma Biotechnology is the larger company by market cap ($531.2 million vs $530.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNPR | PBYI |
|---|---|---|
| Share price | $78.96 | $10.29 |
| Market cap | $529.99M | $531.17M |
| 1-day change | -5.98% | +3.21% |
| YTD return | +20.92% | +72.94% |
| 1-year return | -21.79% | +97.50% |
| 5-year return | +221.63% | +70.08% |
| P/E ratio (TTM) | — | 20.18 |
| Forward P/E | — | 29.40 |
| EPS (TTM) | $-2.20 | $0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $124.82 | $10.35 |
| 52-week low | $50.07 | $4.58 |
| Distance from 52-week high | -36.74% | -0.58% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +64.54% | — |
| Average volume | 213.15K | 320.35K |
| Shares outstanding | 6.71M | 51.62M |
| Employees | 22 | 179 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed MNPR by 119.3 percentage points over the past year.
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
MNPR vs PBYI FAQ
Which is bigger, Monopar Therapeutics or Puma Biotechnology?
Puma Biotechnology (PBYI) is larger, with a market capitalization of $531.17M compared with $529.99M for Monopar Therapeutics (MNPR).
Which stock has performed better over the past year, MNPR or PBYI?
PBYI returned +97.50% over the past 12 months, compared with -21.79% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Monopar Therapeutics and Puma Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.